Navigation Links
Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury
Date:8/3/2009

BELGRADE, Serbia, Aug. 3 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced that researchers in its Slavica BioChem division have reported results on experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored. These experiments were conducted in collaboration with doctors from the Hyperbaric Medical Center, School of Medicine, University of Belgrade, Serbia.

Hyperbaric oxygen (HBO) has been used as a primary or adjunctive therapy over the last 50 years with controversial results, both in experimental and clinical studies. However, the mechanisms underlying the neuroprotective vs. neurodegenerative effects of HBO treatment are still uncertain.

The results of the research group revealed that repetitive HBO treatments, which started 1 hour after traumatic brain injury significantly, reduced axonal loss and neuronal degeneration, suggesting that HBO was able to attenuate the effects of brain damage by reducing the progression of neuronal injury.

These data indicate that HBO-induced prevention of neurodegeneration might be beneficial in improvement of neurological outcome after traumatic brain injury.

Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer said (sic) "The experiments were performed on rats, but since we haven't hyperbaric chambers, HBO treatments were performed at the Hyperbaric Medical Center. These data for the first time showed (all was visualized using immunohistochemical technique and specific antibodies to neuronal markers) that HBO prevent axonal loss and neuronal degeneration, since data concerning brain injury are lacking and are controversial. "

Our Washington Poster will be posted on Pink Sheets Supplemental Info Filing as a pdf.

The results were presented by Professor Mirjana Stojiljkovic. (Professor Stojiljkovic is in the process of becoming HTDS Medical Advisor - Officer of the company). In a summary, Poster presentation was available for review by attendees at the 38th Annual Meeting of Society for Neuroscience's (SfN) http://www.sfn.org/am2008/ held Nov. 15 to 19, 2008 in Washington, DC, USA. Professor Stojiljkovic reported that poster attracted numerous scientists and medical doctors, and for close to 4 hours discussion on this topic continued. Each year SfN provides the premier venue for neuroscientists to share research findings. By attending lectures, symposia, and workshops, meeting attendees experience the most exciting and cutting-edge research the field of neuroscience has to offer. SfN's annual meeting draws diverse attendees from all over the world.

In other company news, along with the Washington poster filing the company expects to be in a position to file its Q2 financial results, and an updated Pink Sheets Adequate Disclosure with a legal opinion shortly and perhaps as early as this week. Mr.Terry Yuan HTDS CEO said " These are exciting times for us at HTDS. There are a lot of moving parts now within HTDS, which are all positive, and which may have more than better than expected results for us as a whole organization. This includes our IP claim and our Q2 financial statements which are currently being translated from Chinese to USA standards, to name a few. As a company we are pleased to acknowledge that our corporate objectives and set targets are being met.

The company will release further updates as they become available.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
5. Free distribution of insecticide-treated mosquito nets can save lives
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. Broad-based group of physicians calls for improvement in stroke treatment
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
10. Non-medicinal treatment touted for pre-schoolers with ADHD
11. Nonmedicinal treatment touted for preschoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 20, 2017 , ... AMC Health , the leading provider of proven ... trials market. Similar to its approach in demonstrating positive outcomes in the healthcare market, ... proving the value of eVisits to support virtual studies. , In a ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts ... NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their practice ... can cause for some patients, which is why they offer the latest in modern ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage (UA), a multi-channel retailer ... designed to create tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle ... twill. , With trendy looks hitting the medical community, UA Flex is for the ...
(Date:6/20/2017)... ... 20, 2017 , ... MEDI+SIGN, a healthcare technology company that ... Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. , “We are eager ... provide invaluable direction for the company,” says Andrew Hoffman, President of MEDI+SIGN. ...
(Date:6/19/2017)... ... June 19, 2017 , ... The joyful summer wedding ... to be a humdinger. A warm winter and wet spring have created ideal conditions ... one wants to be swatting away pesky mosquitoes when a bride and groom are ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... June 8, 2017   Responding to Heath Ledger,s ... the death of singer Chris Cornell in May, ... International offers a free online psychiatric drug ... and families about psychotropic drug risks. The ... died from an accidental overdose, has called for tighter rules ...
(Date:6/7/2017)... Md. , June 7, 2017  Novavax, Inc., (Nasdaq: ... second of two Phase 2 trials of its RSV F ... of child bearing age have been published in the journal ... publication have been shared in prior scientific conferences). The Company ... in April 2014. Novavax is developing the RSV F Vaccine ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy & Homecare is ... the United States . The Raizer is a ... fallen person up to an almost-standing position within ... operated by one assistant and does not require ... enough that a child can operate it, and ...
Breaking Medicine Technology: